Under the agreement, Patheon will formulate, fill and finish ANX-188 drug product for use in clinical trials, including the Phase 3 study of ANX-188 that ADVENTRX plans to initiate in 2012.
ADVENTRX chief executive officer Brian Culley said the agreement is another step toward initiating the Phase 3 study of ANX-188 in patients with sickle cell disease.
"Patheon is a global contract manufacturer that serves more than 300 customers, including many of the world’s largest pharmaceutical and biotechnology companies," Culley added.